Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer.
BACKGROUND
Recently, fibroblast growth factor receptor 1 (FGFR1) was discovered in squamous cell carcinomas (SCC) of the lung with FGFR1 amplification described as a promising predictive marker for anti-FGFR inhibitor treatment. Only few data are available regarding prevalence, prognostic significance and clinico-pathological characteristics of FGFR1-amplified and early-stage non-small cell lung carcinomas (NSCLC). We therefore investigated the FGFR1 gene status in a large number of well-characterised early-stage NSCLC.


METHODS
FGFR1 gene status was evaluated using a commercially available fluorescent in situ hybridisation (FISH) probe on a tissue microarray (TMA). This TMA harbours 329 resected, formalin-fixed and paraffin-embedded, nodal-negative NSCLC with a UICC stage I-II. The FISH results were correlated with clinico-pathological features and overall survival (OS).


RESULTS
The prevalence of an FGFR1 amplification was 12.5% (41/329) and was significantly (P<0.0001) higher in squamous cell carcinoma (SCC) (20.7%) than in adenocarcinoma (2.2%) and large cell carcinoma (13%). Multivariate analysis revealed significantly (P=0.0367) worse 5-year OS in patients with an FGFR1-amplified NSCLC.


CONCLUSIONS
FGFR1 amplification is common in early-stage SCC of the lung and is an independent and adverse prognostic marker. Its potential role as a predictive marker for targeted therapies or adjuvant treatment needs further investigation.
Department of Radiation Oncology, University Hospital/Inselspital Bern and University of Bern, 3010 Bern, Switzerland.
N
N
Cihoric
Institute for Pathology, University Hospital Basel, 4003 Basel, Switzerland.
S
S
Savic
Institute for Pathology, University Hospital Basel, 4003 Basel, Switzerland.
S
S
Schneider
Institute for Pathology, University Hospital Basel, 4003 Basel, Switzerland.
I
I
Ackermann
Institute for Pathology, University Bern, 3010 Bern, Switzerland.
M
M
Bichsel-Naef
Division of General Thoracic Surgery, University Hospital/Inselspital Bern, 3010 Bern, Switzerland.
R A
RA
Schmid
Division of Thoracic Surgery, University Hospital Basel, 4031 Basel, Switzerland.
D
D
Lardinois
1] Institute for Pathology, University Bern, 3010 Bern, Switzerland [2] Promed Laboratoire Médical, 1723 Marley, Switzerland.
M
M
Gugger
Institute for Pathology, University Hospital Basel, 4003 Basel, Switzerland.
L
L
Bubendorf
1] Institute for Pathology, University Hospital Basel, 4003 Basel, Switzerland [2] Institute for Pathology, University Bern, 3010 Bern, Switzerland.
I
I
Zlobec
1] Institute for Pathology, University Hospital Basel, 4003 Basel, Switzerland [2] Institute for Pathology, University Bern, 3010 Bern, Switzerland.
C
C
Tapia
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics* / Q000401:mortality*; D002294:Carcinoma, Squamous Cell / Q000235:genetics* / Q000401:mortality; D018572:Disease-Free Survival; D005260:Female; D005784:Gene Amplification; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D008175:Lung Neoplasms / Q000235:genetics* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000235:genetics; D051496:Receptor, Fibroblast Growth Factor, Type 1 / Q000235:genetics*; D046888:Tissue Array Analysis
C496348:FGFR1 protein, human; D051496:Receptor, Fibroblast Growth Factor, Type 1